Novo Nordisk, the Danish pharmaceutical giant, has unveiled its ambitious plan to invest $158 million in Brazil's Montes Claros factory, which is responsible for a quarter of the company's insulin production worldwide. This significant financial injection will not only revamp the plant but also support the implementation of sustainable projects.
With its renowned products, Ozempic and Wegovy, gaining popularity as effective weight-loss drugs, Novo Nordisk's decision comes at a propitious time. The Brazilian government announced the investment during an official meeting between President Luiz ... clique aqui para ler mais.